UMass Chan Medical School has licensed a promising siRNA-based technology to M2DS, a startup company dedicated to advancing the technology as a treatment for MECP2 Duplication Syndrome. This marks a major step forward in translating cutting-edge research into clinical reality. The technology was developed in the lab of Dr. Khvorova, with the project led by […]
EN EN 
DE
FR
ES
PT
IT
PL
HU
EL
HR
TR
NL
DA
TH
JA
RU
